<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111431983</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111431983</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Canadian Home Total Parenteral Nutrition (HTPN) Registry</article-title>
<subtitle>Vitamin K Supplementation and Bone Mineral Density</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Aljarallah</surname><given-names>Badr</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0148607111431983">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fernandes</surname><given-names>Gail</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="aff1-0148607111431983">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jeejeebhoy</surname><given-names>Khursheed N.</given-names></name>
<degrees>MBBS, PhD, FRCPC</degrees>
<xref ref-type="aff" rid="aff2-0148607111431983">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gramlich</surname><given-names>Leah M.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff3-0148607111431983">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Whittaker</surname><given-names>J. S.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff4-0148607111431983">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Armstrong</surname><given-names>David</given-names></name>
<degrees>MB, BChir, FRCPC, FRCP(UK)</degrees>
<xref ref-type="aff" rid="aff5-0148607111431983">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Duerksen</surname><given-names>Don R.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff6-0148607111431983">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Allard</surname><given-names>Johane P.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0148607111431983">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111431983"><label>1</label>University Health Network, Toronto General Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff2-0148607111431983"><label>2</label>St Michael’s Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff3-0148607111431983"><label>3</label>Alberta Health Services, Edmonton, Alberta, Canada</aff>
<aff id="aff4-0148607111431983"><label>4</label>BC Home Parenteral Nutrition Program, Vancouver, British Columbia, Canada</aff>
<aff id="aff5-0148607111431983"><label>5</label>Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada</aff>
<aff id="aff6-0148607111431983"><label>6</label>Manitoba Home Nutrition Program, St Boniface Hospital, Winnipeg, Manitoba, Canada</aff>
<author-notes>
<corresp id="corresp1-0148607111431983">Johane P. Allard, MD, FRCPC, University Health Network, 585 University Avenue, 9N-973, Toronto, M5G 2C4, Canada; e-mail: <email>Dr.Johane.Allard@uhn.on.ca</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>415</fpage>
<lpage>420</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>1</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Vitamin K supplementation improves bone health, and its absence might be associated with low bone mineral density (BMD). The authors aim to assess vitamin K supplementation practices in Canadian home parenteral nutrition (HPN) programs and their relationship with BMD. <italic>Methods</italic>: This is a cross-sectional study of 189 patients from the Canadian HPN registry. <italic>Results</italic>: All 189 patients studied received M.V.I.-12, which does not contain vitamin K. Of those, 41.3% were supplemented with 10 mg of intravenous vitamin K (VK+) weekly, whereas the others did not receive vitamin K except via lipid emulsion (VK−). Short bowel syndrome accounted for 69% of VK+ and 46% of VK− patients. On univariate analysis, VK+ patients had substantially lower body mass index (BMI) and received lower bisphosphonate infusion than did VK−patients. There were no statistically significant differences in HPN calcium or lipid content, liver function test results, age, sex, or reason for HPN between the 2 groups. Patients who were VK+ had higher lumbar spine T scores and hip T scores than did VK−patients. General linear modeling analysis, adjusted for BMI, age, PN magnesium, PN phosphate, PN calcium, and bisphosphonate as possible predictors of BMD, showed a trend toward better hip T scores (P = .063) for VK+ patients compared with VK− patients. <italic>Conclusion</italic>: In HPN patients supplemented with vitamin K, the trend toward a better hip BMD compared with no supplementation suggests a role for vitamin K in preserving BMD. This requires further study.</p>
</abstract>
<kwd-group>
<kwd>vitamin K</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>bone mineral density</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111431983">
<title>Clinical Relevancy Statement</title>
<p>The current practice of home parenteral nutrition (HPN) programs in Canada is to add vitamin K to PN solutions because M.V.I.-12 does not contain vitamin K. However, some Canadian centers rely on lipid emulsion to provide vitamin K and do not provide additional supplementation. Although this practice might be acceptable to maintain a normal international normalized ratio for inpatients receiving PN, it might adversely affect bone mineral density in long-term HPN patients.</p>
</sec>
<sec id="section2-0148607111431983" sec-type="intro">
<title>Introduction</title>
<p>Vitamin K is an essential element for complete nutrition. It was first isolated in 1930 from alfalfa sprouts. Three forms of vitamin K are available, of which the main source is vitamin K1 (phylloquinone) from plants, such as green vegetables.<sup><xref ref-type="bibr" rid="bibr1-0148607111431983">1</xref></sup> The other forms are vitamin K2 (menAQuinone), synthesized by microflora in the gut, and the synthetic form, vitamin K3 (minadinone), which is converted to menAQuinone by bacteria in the gastrointestinal tract.<sup><xref ref-type="bibr" rid="bibr2-0148607111431983">2</xref></sup> Vitamin K is a cofactor for several physiologic pathways, including coagulation, cell differentiation, and NAD(P)/NAD(P)H via the oxidation reduction cycle.<sup><xref ref-type="bibr" rid="bibr3-0148607111431983">3</xref></sup></p>
<p>In 1985, vitamin K requirements were reported as 150 µg/wk<sup><xref ref-type="bibr" rid="bibr4-0148607111431983">4</xref></sup>; however, subsequent studies have led to regular updates by the Food and Nutrition Board of the Institute of Medicine.<sup><xref ref-type="bibr" rid="bibr5-0148607111431983">5</xref></sup> The current dietary reference intakes for vitamin K are 120 µg/d for men and 90 µg/d for women.<sup><xref ref-type="bibr" rid="bibr5-0148607111431983">5</xref></sup> The absorption of vitamin K appears to depend on the vehicle of delivery.<sup><xref ref-type="bibr" rid="bibr6-0148607111431983">6</xref></sup> Studies show that several factors derived from intestinal bacteria influence the metabolism of vitamin K; dietary vitamin K has an estimated bioavailability of around 15%−20%.<sup><xref ref-type="bibr" rid="bibr7-0148607111431983">7</xref></sup>
</p>
<p>Patients receiving parenteral nutrition (PN) get their vitamin K from different sources. Generally, these patients get vitamin K supplementation in the form of vitamin K1, which is commercially available at different doses. In several Canadian home parenteral nutrition (HPN) programs, the current practice is to add vitamin K to PN solution because the available M.V.I.-12 multivitamin solution does not contain vitamin K, as opposed to in the United States, where the commonly used multivitamin solution is M.V.I. Adult, which contains 150 µg of vitamin K. The reported practice in some Canadian centers is to supplement patients with 10 mg of vitamin K intravenously once a week, which is added to the PN bag along with the other additives. However, other centers do not add vitamin K because the lipid component of PN provides an average dose of 0.05–0.7 µg/mL of vitamin K, depending on the lipid formula. This was shown to be sufficient to maintain a normal international normalized ratio (INR),<sup><xref ref-type="bibr" rid="bibr8-0148607111431983">8</xref></sup> but it is unknown whether this practice will influence bone mineral density (BMD). In this study, we aimed to assess vitamin K supplementation practices in Canadian HPN programs and to assess the relationship between vitamin K supplementation and BMD.</p>
</sec>
<sec id="section3-0148607111431983" sec-type="methods">
<title>Methods</title>
<p>This was a cross-sectional study that included all patients from 6 large academic HPN programs across Canada participating in the Canadian Home Total Parenteral Nutrition Registry. The registry was established in 2005 as an Internet database and is managed by Dr J. Allard and her team. To participate in the registry, each program needs its own institutional ethics board approval, after which the program’s HPN team receives instructions and passwords that allow access to the registry. Each patient is assigned a code to maintain confidentiality, and an electronic record is created on the Web site for each patient. Data are entered using the patients’ medical records, either directly into the Web site registry or via case report forms for subsequent data entry. Each participating HPN program has access to data only on its own patients.</p>
<sec id="section4-0148607111431983">
<title>Sample cohort</title>
<p>All patients enrolled in the registry were included in this study. A detailed history was obtained from the registry, which included the following data from each patient: demography; thrombosis history; history of bisphosphonate therapy; physical examination results; results of biochemical investigations, including liver function tests; coagulation profile; calcium, phosphate, creatinine, urea, vitamin B12, parathyroid hormone, and vitamin D levels; and lipid profile. Nutrition parameters were also obtained and included nutrition intake, indication for HPN, type of lipid solution, HPN regimen and schedule, body mass index (BMI), and BMD.</p>
<p>Once we established the practice of vitamin K supplementation, we compared data between patients receiving (VK+) and not receiving (VK−) vitamin K supplementation.</p>
</sec>
<sec id="section5-0148607111431983">
<title>Statistical analysis</title>
<p>Statistical analyses were performed using SPSS version 16 (SPSS, Inc, an IBM Company, Chicago, IL); descriptive statistics were used. In addition, χ<sup>2</sup> tests were used for categorical variables and the Mann-Whitney <italic>U</italic> test for continuous variables; <italic>P</italic> &lt; .05 was considered statistically significant. A general linear model was used to assess the interaction effects of vitamin K, BMI, age, and magnesium, calcium, phosphate, and bisphosphonate supplementation on BMD. Subgroup analyses were performed for patients with short bowel syndrome (SBS). Results are presented as median (range).</p>
</sec>
</sec>
<sec id="section6-0148607111431983" sec-type="results">
<title>Results</title>
<p>Data were available for 189 HPN patients. Among these patients, 78 (41.3%) were VK+, whereas the rest (111 participants) were not (<xref ref-type="table" rid="table1-0148607111431983">Table 1</xref>). We compared the BMD and other interaction effects between VK+ and VK− participants.</p>
<table-wrap id="table1-0148607111431983" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Demographics and Nutrition Parameters</p>
</caption>
<graphic alternate-form-of="table1-0148607111431983" xlink:href="10.1177_0148607111431983-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Intravenous Vitamin K</th>
<th align="center">Yes (n = 78)</th>
<th align="center">No (n = 111)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn2-0148607111431983">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>53 (19–79)</td>
<td>67 (20–87)</td>
<td>.990</td>
</tr>
<tr>
<td colspan="4">Sex<sup><xref ref-type="table-fn" rid="table-fn3-0148607111431983">b</xref></sup></td>
</tr>
<tr>
<td> Male</td>
<td>28/75 (37.3)</td>
<td>33/110 (30)</td>
<td>.223</td>
</tr>
<tr>
<td> Female</td>
<td>47/75 (62.7)</td>
<td>77/110 (70)</td>
<td/>
</tr>
<tr>
<td>No. of months on HPN</td>
<td>22 (0–123)</td>
<td>18 (0–318)</td>
<td>.465</td>
</tr>
<tr>
<td>Days per week on HPN</td>
<td>7 (2–7)</td>
<td>7 (2–7)</td>
<td>.418</td>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup></td>
<td>20 (14–34)</td>
<td>21 (13–41)</td>
<td>.003</td>
</tr>
<tr>
<td>Quality of life</td>
<td>60 (20–100)</td>
<td>60 (40–100)</td>
<td>.366</td>
</tr>
<tr>
<td>Lipid 20%, mL/d</td>
<td>200 (0–400)</td>
<td>163 (0–560)</td>
<td>.252</td>
</tr>
<tr>
<td>PN phosphate, mmol/d</td>
<td>10 (0–120)</td>
<td>8 (0–35)</td>
<td>.209</td>
</tr>
<tr>
<td>PN Mg, mmol/d</td>
<td>9.75 (2–29)</td>
<td>10 (0–30)</td>
<td>.127</td>
</tr>
<tr>
<td>PN Ca, mmol/d</td>
<td>5 (0–50)</td>
<td>5 (0–20)</td>
<td>.113</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111431983">
<p>Values presented as median (range) except where otherwise indicated. BMI, body mass index; Ca, calcium; HPN, home parenteral nutrition; Mg, magnesium; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn2-0148607111431983">
<label>a</label>
<p><italic>P</italic> value is calculated using Mann-Whitney tests for continuous variables and χ<sup>2</sup> tests for categorical variables.</p>
</fn>
<fn id="table-fn3-0148607111431983">
<label>b</label>
<p>Frequency (%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The median age was 53 (19–79) years for VK+ patients (62.7% of whom were women) and 67 (20–87) years for VK− patients (70% of whom were women). The primary indication for HPN was SBS (VK+, 69%; VK−, 46%); other indications included motility disorders (VK+, 12%; VK−, 7%), mucosal disorders (VK+, 6%; VK−, 4%), malignancy (VK+, 1%; VK−, 6%), and surgical indications (VK+, 4%; VK−, 13%). The group taking vitamin K supplementation had a significantly lower BMI compared with the group without vitamin K (VK+, 20 [14–34] vs VK−, 21 [13–41] kg/m<sup>2</sup>; <italic>P</italic> = .003). There were no other statistically significant differences with respect to PN calcium, magnesium, or phosphate supplements or PN lipid content (<xref ref-type="table" rid="table1-0148607111431983">Table 1</xref>). In terms of laboratory results, there were no significant differences between groups, except with respect to serum bilirubin levels, which were significantly higher in the VK+ group (VK+, 10 [2–437] vs VK−, 7 [2–237] µmol/L; <italic>P</italic> = .002). Other liver enzymes and albumin levels were similar between groups. Although medications are reported in the registry, data on heparin or warfarin (Coumadin) use were not reported consistently and thus insufficient for analysis. Smoking status was unknown for 87% of the patients. There were no records of steroid use.</p>
<p>The proportion of patients taking bisphosphonate was significantly higher in the group without vitamin K (VK+, 12/78 [15.4%] vs VK−, 39/111 [35.1%]; <italic>P</italic> = .003). The group taking vitamin K had a higher BMD than the group without vitamin K, based on lumbar spine T scores (VK+, –1.1 [-4.6 to 1.4] vs VK−, –2.3 [–4.0 to 3.7]; <italic>P</italic> ≤ .001) and hip T scores (VK+, –1.3 [–3.7 to 1.7] vs VK−, –2.1 [–5.0 to 2.3]; <italic>P</italic> = .0039) (<xref ref-type="table" rid="table2-0148607111431983">Table 2</xref>).</p>
<table-wrap id="table2-0148607111431983" position="float">
<label>Table 2.</label>
<caption>
<p>Comparision of Bone Mineral Density Results</p>
</caption>
<graphic alternate-form-of="table2-0148607111431983" xlink:href="10.1177_0148607111431983-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Vitamin K Group, Median (Range)</th>
<th align="center">Non–Vitamin K Group, Median (Range)</th>
<th align="center"><italic>r</italic><sup>2</sup></th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn5-0148607111431983">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Spine T score, g/cm<sup>2</sup></td>
<td>−1.1 (–4.6 to 1.4)</td>
<td>−2.3 (–4.0 to 3.7)</td>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td colspan="3">GLM spine T score, g/cm<sup>2</sup></td>
<td>0.149</td>
<td>.336</td>
</tr>
<tr>
<td>Spine <italic>z</italic> score, g/cm<sup>2</sup></td>
<td>−0.7 (–3.2 to 1.7)</td>
<td>−1.4 (–3.0 to 0.9)</td>
<td/>
<td>.131</td>
</tr>
<tr>
<td>Hip T score, g/cm<sup>2</sup></td>
<td>−1.3 (–3.7 to 2.7)</td>
<td>−2.1 (–5.0 to 2.3)</td>
<td/>
<td>.039</td>
</tr>
<tr>
<td colspan="3">GLM hip T score, g/cm<sup>2</sup></td>
<td>0.238</td>
<td>.063</td>
</tr>
<tr>
<td>Hip <italic>z</italic> score, g/cm<sup>2</sup></td>
<td>−1.0 (–2.5 to 2.0)</td>
<td>−1.4 (–3.9 to 0.6)</td>
<td/>
<td>.229</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607111431983">
<p>GLM, general linear model. The model included the following covariates to control for, as well as to assess their interaction effect on, bone mineral density results: patient age, body mass index, bisphosphonate therapy, and parenteral nutrition calcium, magnesium, and phosphate supplementation.</p>
</fn>
<fn id="table-fn5-0148607111431983">
<label>a</label>
<p><italic>P</italic> value is calculated using Mann-Whitney tests for continuous variables and χ<sup>2</sup> tests for categorical variables.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>When a general linear model (adjusted for BMI; age; PN magnesium, phosphate, and calcium; and bisphosphonate intake) was performed, the results showed a trend toward higher T scores for the hips (<italic>P</italic> = .063) in VK+ patients compared with VK− patients (<xref ref-type="table" rid="table2-0148607111431983">Table 2</xref>) but no association with lumbar spine T scores. As there were no significant effects of vitamin K supplementation on BMD results reported in this model, post hoc tests were not performed.</p>
<sec id="section7-0148607111431983">
<title>SBS patient subgroup</title>
<p>Overall, the subgroup of patients with SBS showed results similar to the larger group. This subgroup had longer HPN treatment (53–60 months vs 18–22 months in the larger group [data not compared statistically]), but there was no significant difference between SBS patients for VK+ and VK−. When VK+ was compared to VK−, there was a higher proportion of women in the VK− subgroup (<xref ref-type="table" rid="table3-0148607111431983">Table 3</xref>; VK+, 54% vs VK−, 75.9%; <italic>P</italic> = .021), but age was similar. The VK+ received more PN 20% lipids and phosphate than VK− patients did (VK+, 175 [0.0–400] vs VK−, 122 [0.0–360.0] mL/d [<italic>P</italic> = .006] and VK+, 9.4 [0.5–120.0] vs VK−, 7.0 [0.0–25.7] mmol/d [<italic>P</italic> = .003], respectively). Laboratory results were similar between VK+ and VK− groups with the exception of bilirubin levels, which were higher in VK+ patients (VK+, 11.0 [2.0–437.0] vs VK−, 8.0 [3.0–237.0] µmol/L; <italic>P</italic> = .018).</p>
<table-wrap id="table3-0148607111431983" position="float">
<label>Table 3.</label>
<caption>
<p>Short Bowel Syndrome Patients With and Without Vitamin K</p>
</caption>
<graphic alternate-form-of="table3-0148607111431983" xlink:href="10.1177_0148607111431983-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Vitamin K (n = 50)</th>
<th align="center">No Vitamin K (n = 54)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn7-0148607111431983">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>53.79 ± 1.75</td>
<td>56.79 ± 1.84</td>
<td>.242</td>
</tr>
<tr>
<td>Sex</td>
<td>22/48 (45.8)</td>
<td>13/54 (24.1)</td>
<td>.021</td>
</tr>
<tr>
<td> Male</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Female</td>
<td>26/48 (54.2)</td>
<td>41/54 (75.9)</td>
<td/>
</tr>
<tr>
<td>Lipid 20%, mL/d</td>
<td>175.0 [0.0–400.0]</td>
<td>122.5 [0.0–360.0]</td>
<td>.006</td>
</tr>
<tr>
<td>Number of months on HPN</td>
<td>53.11 ± 15.39</td>
<td>60.07 ± 17.39</td>
<td>.827</td>
</tr>
<tr>
<td>Days per week on HPN</td>
<td>5.5 [2.0–7.0]</td>
<td>5.5 [2.0–7.0]</td>
<td>.420</td>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup></td>
<td>19.58 ± 0.89</td>
<td>21.56 ± 0.78</td>
<td>.097</td>
</tr>
<tr>
<td>BMD</td>
<td>−0.928 ± 0.301</td>
<td>−1.883 ± 0.304</td>
<td>.036</td>
</tr>
<tr>
<td> Spine T score</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Spine <italic>z</italic> score</td>
<td>−0.500 ± 0.320</td>
<td>−1.418 ± 0.233</td>
<td>.025</td>
</tr>
<tr>
<td> Hip T score</td>
<td>−1.100 ± 0.442</td>
<td>−1.963 ± 0.322</td>
<td>.120</td>
</tr>
<tr>
<td> Hip <italic>z</italic> score</td>
<td>−0.820 ± 0.437</td>
<td>−1.6682 ± 0.219</td>
<td>.062</td>
</tr>
<tr>
<td>PN phosphate, mmol/d</td>
<td>9.4 [0.5–120.0]</td>
<td>7.0 [0.0–25.7]</td>
<td>.003</td>
</tr>
<tr>
<td>PN Mg, mmol/d</td>
<td>10.33 ± 0.64</td>
<td>9.60 ± 0.76</td>
<td>.465</td>
</tr>
<tr>
<td>PN Ca, mmol/d</td>
<td>5.59 ± 1.04</td>
<td>5.40 ± 0.58</td>
<td>.874</td>
</tr>
<tr>
<td>Blood Mg, mmol/L</td>
<td>1.24 ± 0.31</td>
<td>0.83 ± 0.02</td>
<td>.197</td>
</tr>
<tr>
<td>Blood Ca, mmol/L</td>
<td>2.39 ± 0.09</td>
<td>2.21 ± 0.04</td>
<td>.063</td>
</tr>
<tr>
<td>Blood phosphate, mmol/L</td>
<td>1.89 ± 0.48</td>
<td>1.20 ± 0.03</td>
<td>.158</td>
</tr>
<tr>
<td>Blood serum urea nitrogen, mmol/L</td>
<td>10.38 ± 2.91</td>
<td>8.39 ± 0.64</td>
<td>.508</td>
</tr>
<tr>
<td>Blood creatinine, mmol/L</td>
<td>85.0 [31.0–245.0]</td>
<td>79.5 [46.0–390.0]</td>
<td>.593</td>
</tr>
<tr>
<td>Random glucose, mmol/L</td>
<td>5.64 ± 0.21</td>
<td>6.18 ± 0.83</td>
<td>.535</td>
</tr>
<tr>
<td>ALP, U/L</td>
<td>181.50 ± 24.39</td>
<td>214.10 ± 26.77</td>
<td>.379</td>
</tr>
<tr>
<td>Bilirubin, µmol/L</td>
<td>11.0 [2.0–437.0]</td>
<td>8.0 [3.0–237.0]</td>
<td>.018</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>33.0 [17.0–266.0]</td>
<td>31.0 [17.0–209.0]</td>
<td>.684</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>39.0 [10.0–198.0]</td>
<td>30.5 [14.0–152.0]</td>
<td>.860</td>
</tr>
<tr>
<td>Total protein, g/L</td>
<td>70.33 ± 1.48</td>
<td>69.6667 ± 1.5779</td>
<td>.767</td>
</tr>
<tr>
<td>Albumin, g/L</td>
<td>37.78 ± 0.90</td>
<td>37.10 ± 0.73</td>
<td>.551</td>
</tr>
<tr>
<td>INR</td>
<td>1.1 [0.9–2.2]</td>
<td>1.0 [0.9–4.7]</td>
<td>.487</td>
</tr>
<tr>
<td>Bisphosphonate</td>
<td>10/50 (20.0)</td>
<td>25/54 (46.3)</td>
<td>.005</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0148607111431983">
<p>Values presented as mean ± SEM (normal) or median [range] or frequency (%). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMD, bone mineral density; BMI, body mass index; Ca, calcium; HPN, home parenteral nutrition; INR, international normalized ratio; Mg, magnesium; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn7-0148607111431983">
<label>a</label>
<p><italic>P</italic> value is calculated using Mann-Whitney tests for continuous variables and χ<sup>2</sup> tests for categorical variables.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As in the larger group, there was a higher proportion of patients on bisphosphonate in the SBS subgroup without vitamin K compared with those on vitamin K (VK+, 10/50 [20.0%] vs VK−, 25/54 [46.3%]; <italic>P</italic> = .005). The group taking vitamin K had higher BMD results when compared with the group without vitamin K, based on lumbar spine T scores (VK+, –0.928 ± 0.301 vs VK−, –1.883 ± 0.304; <italic>P</italic> = .036) but not based on hip T-scores (VK+, –1.1 ± 0.442 vs VK−, –1.963 ± 0.322; <italic>P</italic> = .120). General linear analysis was not conducted owing to the smaller number of patients.</p>
</sec>
</sec>
<sec id="section8-0148607111431983" sec-type="discussion">
<title>Discussion</title>
<p>In this article, univariate analysis showed that HPN patients receiving vitamin K supplementation had significantly higher BMDs than patients not receiving vitamin K in their HPN solution. Although multivariate analyses showed only a trend toward higher hip T scores in those taking vitamin K and no association with lumbar spine T scores, these results might suggest a potential role for vitamin K supplementation and bone health in this patient population. Subgroup analysis using only patients with SBS tends to show similar results. This warrants further study.</p>
<p>The addition of vitamin K to the HPN regimen was recently questioned, and it was suggested that the amount included in lipid emulsions was sufficient to maintain a normal INR. In a Canadian cohort study, one of our authors (D.D.) followed 84 consecutive hospitalized patients receiving PN with lipid emulsions but no vitamin K supplementation for up to 4 weeks to determine the incidence of raised INR. Results showed no significant changes in INR, with the majority of patients in the cohort receiving 150 µg of vitamin K daily via lipid emulsion. The authors concluded that it might be unnecessary to routinely supplement patients with vitamin K if they are receiving a lipid emulsion containing substantial amounts of vitamin K.<sup><xref ref-type="bibr" rid="bibr8-0148607111431983">8</xref></sup> However, this study followed only hospitalized patients requiring short-term administration of PN (&lt;3 weeks),<sup><xref ref-type="bibr" rid="bibr8-0148607111431983">8</xref></sup> and it did not take into consideration the potential role of vitamin K in bone health, particularly for long-term HPN patients.</p>
<p>The role of vitamin K supplementation is typically recognized for the prevention of coagulopathy induced by vitamin K deficiency.<sup><xref ref-type="bibr" rid="bibr9-0148607111431983">9</xref></sup> However, vitamin K is a coenzyme for glutamate carboxylase, which mediates the conversion of glutamate to γ-carboxyglutamic acid (Gla).<sup><xref ref-type="bibr" rid="bibr10-0148607111431983">10</xref></sup> As several Gla proteins are expressed in virtually every tissue of the body, this has subsequently led to a reevaluation of the role of vitamin K in overall health.<sup><xref ref-type="bibr" rid="bibr11-0148607111431983">11</xref>,<xref ref-type="bibr" rid="bibr12-0148607111431983">12</xref></sup> In particular, the role of vitamin K in bone metabolism is mediated through Gla proteins (ie, bone Gla proteins): osteocalcin (OC), matrix Gla proteins, and periostin.<sup><xref ref-type="bibr" rid="bibr9-0148607111431983">9</xref></sup> The best known of the 3 bone-related Gla proteins is OC. Even though the exact role of OC is unknown, a number of studies have shown that vitamin K insufficiency is associated with an increase in the concentration of circulating undercarboxylated OC.<sup><xref ref-type="bibr" rid="bibr3-0148607111431983">3</xref><xref ref-type="bibr" rid="bibr4-0148607111431983"/><xref ref-type="bibr" rid="bibr5-0148607111431983"/><xref ref-type="bibr" rid="bibr6-0148607111431983"/><xref ref-type="bibr" rid="bibr7-0148607111431983"/><xref ref-type="bibr" rid="bibr8-0148607111431983"/><xref ref-type="bibr" rid="bibr9-0148607111431983"/><xref ref-type="bibr" rid="bibr10-0148607111431983"/><xref ref-type="bibr" rid="bibr11-0148607111431983"/><xref ref-type="bibr" rid="bibr12-0148607111431983"/><xref ref-type="bibr" rid="bibr13-0148607111431983"/><xref ref-type="bibr" rid="bibr14-0148607111431983"/><xref ref-type="bibr" rid="bibr15-0148607111431983"/><xref ref-type="bibr" rid="bibr16-0148607111431983"/><xref ref-type="bibr" rid="bibr17-0148607111431983"/><xref ref-type="bibr" rid="bibr18-0148607111431983"/><xref ref-type="bibr" rid="bibr19-0148607111431983"/>-<xref ref-type="bibr" rid="bibr20-0148607111431983">20</xref></sup> Vitamin K supplementation has been shown to improve the bone turnover profile and decrease the level of circulating undercarboxylated OC<sup><xref ref-type="bibr" rid="bibr21-0148607111431983">21</xref></sup> as well as reduce bone loss and decrease fractures.<sup><xref ref-type="bibr" rid="bibr22-0148607111431983">22</xref></sup> Therefore, vitamin K supplementation in the HPN regimen might be of benefit. This is particularly important for HPN patients with very limited oral intake, such as those with motility, obstruction, or significant malabsorption disorders (eg, patients with SBS or high output fistulas)—dietary intake of vitamin K and its absorption can be highly variable in this population and frequently suboptimal. Although there could be some production of vitamin K from bacterial overgrowth,<sup><xref ref-type="bibr" rid="bibr23-0148607111431983">23</xref></sup> depending on the gastrointestinal anatomy of the HPN patients, the use of antibiotics for line infection and treatment of symptomatic bacterial overgrowth is not infrequent in this population. This would result in decreases in vitamin K production. Based on the registry, our 2 groups were comparable in most of these parameters. As all these factors play a role in the bioavailability of vitamin K, dietary recommendations based on saturation of the coagulation system<sup><xref ref-type="bibr" rid="bibr24-0148607111431983">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607111431983">25</xref></sup> mean very little in this population. Furthermore, with regard to bone health, dietary vitamin K requirements might be higher,<sup><xref ref-type="bibr" rid="bibr26-0148607111431983">26</xref></sup> underscoring the importance of vitamin K supplementation in the HPN population. In our study, dietary intake was recorded and entered in the Web site. However, many of these patients have malabsorption, so it is difficult to assess the amount of vitamin K effectively absorbed.</p>
<p>Therefore, most HPN patients receive the bulk of their vitamin K from their PN regimen. The question is, what constitutes the ideal dose of vitamin K and what about the other sources of vitamin K apart from vitamin K1? A small study with 15 adult patients found that 255 µg per week of vitamin K from lipid emulsion in patients with normal vitamin K stores and 418 µper week from lipid emulsion in patients with low vitamin K stores resulted in normalization of vitamin K levels in both groups.<sup><xref ref-type="bibr" rid="bibr27-0148607111431983">27</xref></sup> Another pediatric study showed that patients who received 200 µg vitamin K1 daily, intravenously, had vitamin K concentrations that were 10-fold higher than those of the normal control group.<sup><xref ref-type="bibr" rid="bibr28-0148607111431983">28</xref></sup> In 2000, the Food and Drug Administration (FDA) recommended vitamin K be added to the multivitamin regimen of adult HPN patients at a dose of 150 µg per day; the FDA-mandated supplementary material is vitamin K1, phylloquinone.<sup><xref ref-type="bibr" rid="bibr29-0148607111431983">29</xref></sup>
</p>
<p>For our HPN registry patients, the amount of vitamin K received for the group on vitamin K was 10 mg added once a week to the PN bag along with the multivitamin solution. The commercial multivitamin preparation used in the participating 6 Canadian programs did not contain vitamin K. The other source of vitamin K is lipid emulsion. There was no significant difference in the amount of lipid emulsion provided between groups.</p>
<p>The oils from which lipid emulsions are manufactured contain vitamin K in multiple percentages, depending on the original oil used. The lipid component of the PN provides an average dose of 0.05–0.7 µg/mL of vitamin K, according to the lipid formula. Soybean oil contains between 150 and 300 µg of vitamin K per 100 g of oil, whereas sunflower oil contains 6–12 µg of vitamin K per 100 g of oil.<sup><xref ref-type="bibr" rid="bibr30-0148607111431983">30</xref></sup> Intralipid 20% is the most common lipid emulsion available in Canada; it is made up of 100% soybean oil, with vitamin K contents estimated at 0.6 µg/mL per 20%. As Intralipid 20% is commonly prescribed at 50 g per day, this translates to 150 µg of vitamin K per day.<sup><xref ref-type="bibr" rid="bibr6-0148607111431983">6</xref></sup> This would meet or exceed the FDA recommendations, which are consistent with recommendations by Duerksen and Papineau.<sup><xref ref-type="bibr" rid="bibr8-0148607111431983">8</xref></sup>
</p>
<p>There are other factors affecting bone health in this population. PN has been associated with metabolic bone disease and low BMD.<sup><xref ref-type="bibr" rid="bibr31-0148607111431983">31</xref></sup> Factors such as PN formulation, which include amounts of protein, calcium, phosphate, magnesium, vitamin D, bicarbonate, aluminum, and others,<sup><xref ref-type="bibr" rid="bibr32-0148607111431983">32</xref></sup> can play a role. Underlying inflammatory diseases, such as Crohn disease, might also affect BMD,<sup><xref ref-type="bibr" rid="bibr33-0148607111431983">33</xref></sup> particularly if steroids are used. Another potential factor is chronic cholestasis, which could reduce vitamin K absorption. In our study, the VK+ group had substantially higher serum bilirubin levels and yet also had greater BMDs. This result was constant in the combined cohort as well as in the SBS subgroup. Differences in nutrition status might also play a role. Nutrition status, based on BMI, was normal in both groups, and BMI was significantly higher in VK− patients who had lower BMDs. Therefore, malnutrition did not contribute to lower BMD in this group. Finally, sex ratio and age range were similar between groups for the combined cohort analysis but not for the SBS subgroup analysis.</p>
</sec>
<sec id="section9-0148607111431983">
<title>Limitations</title>
<p>This study has several limitations. The availability of data on anticoagulant prescription rates would have helped us to better understand why some patients did not receive vitamin K. Another limitation is the cross-sectional design, which does not permit the inference of a cause-effect relationship between vitamin K and bone density. In our study, the multivariate analysis controlled for several factors, such as PN calcium, PN magnesium, PN phosphate, age, BMI, and bisphosphonate, and did not show a significant association between vitamin K supplementation and high bone density. The lack of a significant association could be due to the fact that the group was heterogeneous (different PN regimen, gastrointestinal anatomy, underlying diagnosis, etc), requiring a larger sample size. However, we thought that the trend seen with the association between vitamin K supplementation and high bone density in the hip was of interest and could spark interesting hypotheses for future cohort studies.</p>
<p>As with any registry, each HPN program was responsible for entering its own patients; this could have resulted in inconsistencies in the way data were entered, which might explain why some patients were not reported for vitamin K intake. Although the registry was validated for accuracy and agreement between observers, this did not extend to the report on anticoagulants.<sup><xref ref-type="bibr" rid="bibr34-0148607111431983">34</xref></sup> Finally, certain factors that might influence bone density were not collected or validated, such as level of exercise and smoking.</p>
</sec>
<sec id="section10-0148607111431983" sec-type="conclusions">
<title>Conclusion</title>
<p>Some of the Canadian HPN patients enrolled in the registry receive vitamin K supplementation, whereas others do not. For some patients, anticoagulation therapy might be the reason vitamin K supplementation is not received; for others, the practice of some HPN programs is to provide vitamin K via lipid emulsions. In HPN patients, vitamin K supplementation might have a potential benefit to BMD, as our multivariate analysis showed a trend toward higher hip BMD in patients receiving vitamin K supplementation. Subgroup analysis of patients with SBS also showed a higher BMD in those receiving vitamin K; however, a multivariate analysis could not be conducted owing to the small sample size. Prospective cohort studies that control for confounding factors are required to determine whether vitamin K supplementation is beneficial for bone health in HPN patients.</p>
</sec>
</body>
<back>
<ack>
<p>Alberta: Edmonton—Dr Leah Gramlich’s team (Holly Ames, RD, MSc; Lisa Heighington, RN; Marie Hancock, RN)</p>
<p>British Columbia: Vancouver—Dr Scott Whittaker’s team</p>
<p>Manitoba: Winnipeg—Dr. Donald Duerksen’s team</p>
<p>Ontario: Hamilton Health Sciences–McMaster University Medical Centre—Dr David Armstrong’s team (Suzanne Hansen, RD; Stella Stevens, RN)</p>
<p>Ontario: Toronto–St Michael Hospital—Dr K. N. Jeejeebhoy’s team (Clare Meechan, RN; Brian Jurewitsch, PharmD; Fiona Press, RD)</p>
<p>Ontario: Toronto General Hospital—Dr Johane P. Allard’s team (Olivia SAQui, RN; Lydia Fairholm, RD; Mary Baun, BPharm; Mille Yeung, BPharm)</p>
<p>Twenty One Ton, Toronto, Ontario—Andrew Shaw</p>
<p>HTPN Registry sponsors: Calea, Inc and Baxter, Inc</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111431983">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furie</surname><given-names>B</given-names></name>
<name><surname>Bouchard</surname><given-names>B</given-names></name>
<name><surname>Furie</surname><given-names>BC</given-names></name>
</person-group>. <article-title>Vitamin K–dependent biosynthesis of gamma-carboxyglutamic acid</article-title>. <source>Blood</source>. <year>1999</year>;<volume>93</volume>:<fpage>1798</fpage>-<lpage>1808</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111431983">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furie</surname><given-names>B</given-names></name>
</person-group>. <article-title>Molecular basis of vitamin K dependent gammacarboxylation</article-title>. <source>Blood</source>. <year>1990</year>;<volume>75</volume>:<fpage>1753</fpage>-<lpage>1762</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111431983">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bern</surname><given-names>M</given-names></name>
</person-group>. <article-title>Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>388</fpage>-<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111431983">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hands</surname><given-names>LJ</given-names></name>
<name><surname>Royle</surname><given-names>GT</given-names></name>
<name><surname>Kettlewell</surname><given-names>MG</given-names></name>
</person-group>. <article-title>Vitamin K requirements in patients receiving total parenteral nutrition</article-title>. <source>Br J Surg</source>. <year>1985</year>;<volume>72</volume>:<fpage>665</fpage>-<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111431983">
<label>5.</label>
<citation citation-type="book">
<collab>Institute of Medicine, Food and Nutrition Board</collab>. <source>Dietary Reference Intake for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc: A Report of the Panel on Micro-Nutrients</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2001</year>.</citation>
</ref>
<ref id="bibr6-0148607111431983">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duerksen</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Central venous thrombosis in patients receiving long-term parenteral nutrition</article-title>. <source>Appl Physiol Nutr Metab</source>. <year>2008</year>;<volume>33</volume>:<fpage>32</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111431983">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garber</surname><given-names>AK</given-names></name>
<name><surname>Binkley</surname><given-names>NC</given-names></name>
<name><surname>Krueger</surname><given-names>DC</given-names></name>
<name><surname>Suttie</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects</article-title>. <source>J Nutr</source>. <year>1999</year>;<volume>129</volume>:<fpage>1201</fpage>-<lpage>1203</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111431983">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duerksen</surname><given-names>DR</given-names></name>
<name><surname>Papineau</surname><given-names>N</given-names></name>
</person-group>. <article-title>The prevalence of coagulation abnormalities in hospitalized patients receiving lipid-based parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>30</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111431983">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shearer</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Vitamin K in parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S105</fpage>-<lpage>S118</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111431983">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stenflo</surname><given-names>J</given-names></name>
</person-group>. <article-title>From gamma-carboxy-glutamate to protein C</article-title>. <source>J Thromb Haemost</source>. <year>2006</year>;<volume>4</volume>:<fpage>2521</fpage>-<lpage>2526</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111431983">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vermeer</surname><given-names>C</given-names></name>
<name><surname>Shearer</surname><given-names>MJ</given-names></name>
<name><surname>Zittermann</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health</article-title>. <source>Eur J Nutr</source>. <year>2004</year>;<volume>43</volume>:<fpage>325</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111431983">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berkner</surname><given-names>KL</given-names></name>
<name><surname>Runge</surname><given-names>KW</given-names></name>
</person-group>. <article-title>The physiology of vitamin K nutriture and vitamin K–dependent protein function in atherosclerosis</article-title>. <source>J Thromb Haemost</source>. <year>2004</year>;<volume>2</volume>:<fpage>2118</fpage>-<lpage>2132</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111431983">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binkley</surname><given-names>NC</given-names></name>
<name><surname>Krueger</surname><given-names>DC</given-names></name>
<name><surname>Engelke</surname><given-names>JA</given-names></name>
<name><surname>Foley</surname><given-names>AL</given-names></name>
<name><surname>Suttie</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults</article-title>. <source>Am J Clin Nutr</source>. <year>2000</year>;<volume>72</volume>:<fpage>1523</fpage>-<lpage>1528</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111431983">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Booth</surname><given-names>SL</given-names></name>
<name><surname>Lichtenstein</surname><given-names>AH</given-names></name>
<name><surname>O’Brien-Morse</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Effects of a hydrogenated form of vitamin K on bone formation and resorption</article-title>. <source>Am J Clin Nutr</source>. <year>2001</year>;<volume>74</volume>:<fpage>783</fpage>-<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111431983">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Booth</surname><given-names>SL</given-names></name>
<name><surname>Martini</surname><given-names>L</given-names></name>
<name><surname>Peterson</surname><given-names>JW</given-names></name>
<name><surname>Saltzman</surname><given-names>E</given-names></name>
<name><surname>Dallal</surname><given-names>GE</given-names></name>
<name><surname>Wood</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Dietary phylloquinone depletion and repletion in older women</article-title>. <source>J Nutr</source>. <year>2003</year>;<volume>133</volume>:<fpage>2565</fpage>-<lpage>2569</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111431983">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bügel</surname><given-names>S</given-names></name>
<name><surname>Sørensen</surname><given-names>AD</given-names></name>
<name><surname>Hels</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women</article-title>. <source>Br J Nutr</source>. <year>2007</year>;<volume>97</volume>:<fpage>373</fpage>-<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111431983">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collins</surname><given-names>A</given-names></name>
<name><surname>Cashman</surname><given-names>KD</given-names></name>
<name><surname>Kiely</surname><given-names>M</given-names></name>
</person-group>. <article-title>Phylloquinone (vitamin K1) intakes and serum undercarboxylated osteocalcin levels in Irish postmenopausal women</article-title>. <source>Br J Nutr</source>. <year>2006</year>;<volume>95</volume>:<fpage>982</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111431983">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craciun</surname><given-names>AM</given-names></name>
<name><surname>Wolf</surname><given-names>J</given-names></name>
<name><surname>Knapen</surname><given-names>MHJ</given-names></name>
<name><surname>Brouns</surname><given-names>F</given-names></name>
<name><surname>Vermeer</surname><given-names>C</given-names></name>
</person-group>. <article-title>Improved bone metabolism in female elite athletes after vitamin K supplementation</article-title>. <source>Int J Sports Med</source>. <year>1998</year>;<volume>19</volume>:<fpage>479</fpage>-<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111431983">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Knapen</surname><given-names>MHJ</given-names></name>
<name><surname>Hamulyák</surname><given-names>K</given-names></name>
<name><surname>Vermeer</surname><given-names>C</given-names></name>
</person-group>. <article-title>The effect of vitamin K supplementation on circulating osteocalcin (bone GLA protein) and urinary calcium excretion</article-title>. <source>Ann Intern Med</source>. <year>1989</year>;<volume>111</volume>:<fpage>1001</fpage>-<lpage>1005</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111431983">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schaafsma</surname><given-names>A</given-names></name>
<name><surname>Muskiet</surname><given-names>FA</given-names></name>
<name><surname>Storm</surname><given-names>H</given-names></name>
<name><surname>Hofstede</surname><given-names>GJ</given-names></name>
<name><surname>Pakan</surname><given-names>I</given-names></name>
<name><surname>Van der Veer</surname><given-names>E</given-names></name>
</person-group>. <article-title>Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin</article-title>. <source>Eur J Clin Nutr</source>. <year>2000</year>;<volume>54</volume>:<fpage>626</fpage>-<lpage>631</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111431983">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKeown</surname><given-names>NM</given-names></name>
<name><surname>Jacques</surname><given-names>PF</given-names></name>
<name><surname>Gundberg</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Dietary and nondietary determinants of vitamin K biochemical measures in men and women</article-title>. <source>J Nutr</source>. <year>2002</year>;<volume>132</volume>:<fpage>1329</fpage>-<lpage>1334</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111431983">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cockayne</surname><given-names>S</given-names></name>
<name><surname>Adamson</surname><given-names>J</given-names></name>
<name><surname>Lanham-New</surname><given-names>S</given-names></name>
<name><surname>Shearer</surname><given-names>M</given-names></name>
<name><surname>Gilbody</surname><given-names>S</given-names></name>
<name><surname>Torgerson</surname><given-names>D</given-names></name>
</person-group>. <article-title>Vitamin K and the prevention of fractures</article-title>. <source>Arch Intern Med</source>. <year>2006</year>;<volume>166</volume>:<fpage>1256</fpage>-<lpage>1261</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111431983">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Conly</surname><given-names>J</given-names></name>
<name><surname>Stein</surname><given-names>K</given-names></name>
</person-group>. <article-title>Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials</article-title>. <source>Clin Invest Med</source>. <year>1994</year>;<volume>17</volume>:<fpage>531</fpage>-<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111431983">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suttie</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Vitamin K and human nutrition</article-title>. <source>J Am Diet Assoc</source>. <year>1992</year>;<volume>92</volume>:<fpage>585</fpage>-<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111431983">
<label>25.</label>
<citation citation-type="book">
<article-title>Food and Nutrition Board, Commission on Life Sciences, National Research Council</article-title>. <source>Recommended Dietary Allowances</source>. <edition>10th ed.</edition> <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>1989</year>.</citation>
</ref>
<ref id="bibr26-0148607111431983">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bugel</surname><given-names>S</given-names></name>
</person-group>. <article-title>Vitamin K and bone health in adult humans</article-title>. <source>Vitamins Hormones</source>. <year>2008</year>;<volume>78</volume>:<fpage>393</fpage>-<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111431983">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chambrier</surname><given-names>C</given-names></name>
<name><surname>Leclercq</surname><given-names>M</given-names></name>
<name><surname>Saudin</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Is vitamin K1 supplementation necessary in long-term parenteral nutrition?</article-title> <source>JPEN J Parenter Enteral Nutr</source>. <year>1998</year>;<volume>22</volume>:<fpage>87</fpage>-<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111431983">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pettei</surname><given-names>MJ</given-names></name>
<name><surname>Israel</surname><given-names>D</given-names></name>
<name><surname>Levine</surname><given-names>J</given-names></name>
</person-group>. <article-title>Serum vitamin K concentration in pediatric patients receiving total parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1993</year>;<volume>17</volume>:<fpage>465</fpage>-<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111431983">
<label>29.</label>
<citation citation-type="journal">
<source>Fed Reg</source>. <year>2000</year>;<volume>65</volume>:<fpage>64607</fpage>-<lpage>64619</lpage>.</citation>
</ref>
<ref id="bibr30-0148607111431983">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferland</surname><given-names>G</given-names></name>
<name><surname>Sadowski</surname><given-names>JA</given-names></name>
</person-group>. <article-title>The vitamin K2 (phylloquinone)content of edible oils: effects of heating and light exposure</article-title>. <source>J Agric Food Chem Res</source>. <year>1992</year>;<volume>40</volume>:<fpage>1869</fpage>-<lpage>1873</lpage>.</citation>
</ref>
<ref id="bibr31-0148607111431983">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Booth</surname><given-names>SL</given-names></name>
<name><surname>Broe</surname><given-names>KE</given-names></name>
<name><surname>Gagnon</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. <article-title>vitamin K intake and bone mineral density in women and men</article-title>. <source>Am J Clin Nutr</source>. <year>2003</year>;<volume>77</volume>:<fpage>512</fpage>-<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr32-0148607111431983">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buchman</surname><given-names>AL</given-names></name>
<name><surname>Moukarzel</surname><given-names>A</given-names></name>
</person-group>. <article-title>Metabolic bone disease associated with total parenteral nutrition</article-title>. <source>Clin Nutr</source>. <year>2000</year>;<volume>19</volume>:<fpage>217</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr33-0148607111431983">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bjarnason</surname><given-names>I</given-names></name>
<name><surname>Macpherson</surname><given-names>A</given-names></name>
<name><surname>Mackintosh</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Reduced bone density in patients with inflammatory bowel disease</article-title>. <source>Gut</source>. <year>1997</year>;<volume>40</volume>(<issue>2</issue>):<fpage>228</fpage>-<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr34-0148607111431983">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>G</given-names></name>
<name><surname>Kaila</surname><given-names>B</given-names></name>
<name><surname>Saqui</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Canadian Home Total Parenteral Nutrition (HTPN) Registry: validation of data entry in a subset of HTPN patients</article-title>. <source>Nutr Clin Pract</source>. <year>2010</year>;<volume>25</volume>(<issue>1</issue>):<fpage>S29</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>